The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2015 | Dose adherence and baseline exposure analysis of ibrutinib for relapsed/refractory CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, NY, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton’s tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukemia (CLL) from the phase 3 RESONATE trial.
